305 related articles for article (PubMed ID: 30372384)
1. Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers.
Signoretti S; Flaifel A; Chen YB; Reuter VE
J Clin Oncol; 2018 Oct; 36(36):JCO2018792259. PubMed ID: 30372384
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
3. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
5. Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma.
Yalcin S; Lacin S
Cancer Manag Res; 2019; 11():7779-7785. PubMed ID: 31496820
[TBL] [Abstract][Full Text] [Related]
6. Clear Cell Papillary Renal Cell Carcinoma: A Recent Entity With Distinct Imaging Patterns.
Tordjman M; Dbjay J; Chamouni A; Morini A; Timsit MO; Mejean A; Vasiliu V; Eiss D; Correas JM; Verkarre V; Helenon O
AJR Am J Roentgenol; 2020 Mar; 214(3):579-587. PubMed ID: 31770020
[No Abstract] [Full Text] [Related]
7. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
Golshayan AR; Brick AJ; Choueiri TK
Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
[TBL] [Abstract][Full Text] [Related]
8. Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers.
Iacovelli R; Arduini D; Ciccarese C; Pierconti F; Strusi A; Piro G; Carbone C; Foschi N; Daniele G; Tortora G
Crit Rev Oncol Hematol; 2022 Aug; 176():103750. PubMed ID: 35728738
[TBL] [Abstract][Full Text] [Related]
9. Renal cell carcinoma of end-stage renal disease: a histopathologic and molecular genetic study.
Hughson MD; Schmidt L; Zbar B; Daugherty S; Meloni AM; Silva FG; Sandberg AA
J Am Soc Nephrol; 1996 Nov; 7(11):2461-8. PubMed ID: 8959640
[TBL] [Abstract][Full Text] [Related]
10. Loss of Von Hippel-Lindau (
Kim H; Shim BY; Lee SJ; Lee JY; Lee HJ; Kim IH
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575959
[TBL] [Abstract][Full Text] [Related]
11. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S
Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929
[TBL] [Abstract][Full Text] [Related]
12. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
13. The role of inflammation in kidney cancer.
de Vivar Chevez AR; Finke J; Bukowski R
Adv Exp Med Biol; 2014; 816():197-234. PubMed ID: 24818725
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
15. Mutations in renal cell carcinoma.
D'Avella C; Abbosh P; Pal SK; Geynisman DM
Urol Oncol; 2020 Oct; 38(10):763-773. PubMed ID: 30478013
[TBL] [Abstract][Full Text] [Related]
16. Distinctive clinicopathological features of Von Hippel-Lindau-associated hereditary renal cell carcinoma: A single-institution study.
Hong B; Zhang Z; Zhou J; Ma K; Zhang J; Cai L; Zhang N; Gong K
Oncol Lett; 2019 May; 17(5):4600-4606. PubMed ID: 30944649
[TBL] [Abstract][Full Text] [Related]
17. CAIX and pax-8 Commonly Immunoreactive in Endolymphatic Sac Tumors: A Clinicopathologic Study of 26 Cases with Differential Considerations for Metastatic Renal Cell Carcinoma in von Hippel-Lindau Patients.
Thompson LDR; Magliocca KR; Andreasen S; Kiss K; Rooper L; Stelow E; Wenig BM; Bishop JA
Head Neck Pathol; 2019 Sep; 13(3):355-363. PubMed ID: 30291511
[TBL] [Abstract][Full Text] [Related]
18. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
19. Metastatic renal cell carcinoma versus pancreatic neuroendocrine tumor in von Hippel-Lindau disease: treatment with interleukin-2.
Williams C; Walther M
ScientificWorldJournal; 2005 Jan; 5():9-10. PubMed ID: 15674444
[TBL] [Abstract][Full Text] [Related]
20. Clear cell endocrine pancreatic tumor mimicking renal cell carcinoma: a distinctive neoplasm of von Hippel-Lindau disease.
Hoang MP; Hruban RH; Albores-Saavedra J
Am J Surg Pathol; 2001 May; 25(5):602-9. PubMed ID: 11342771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
